Dr Lal PathLabs Ltd.'s third quarter profit surged, in line with analysts' estimates.
The diagnostic and healthcare testing services provider's net profit rose 53% year-on-year to Rs 82 crore in the quarter ended December, according to its exchange filing. That compares with the Rs 79-crore consensus estimate of analysts tracked by Bloomberg.
Sequentially, profit was down by 26%.
Dr Lal PathLabs Q3 FY24 Highlights (YoY)
Revenue rose 10% to Rs 539 crore as against an estimate of Rs 558 crore.
Ebitda was up 24% to Rs 141 crore, as compared with an estimate of Rs 141 crore.
Margin expanded to 26.1% from 23.1% a year ago. Analysts had forecast it at 25.3%.
The company has approved a second interim dividend of Rs 12 per share.
Shares of Dr Lal PathLabs gained 0.45% after the results were announced, as compared with a 0.11% decline in the benchmark Sensex as of 1:43 p.m. on Thursday.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
